Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.

CH, Köhne; M, Karthaus; L, Mineur; J, Thaler; den Eynde M, Van; J, Gallego; R, Koukakis; M, Berkhout; RD, Hofheinz

doi:10.1007/s40268-019-0278-8

Public

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.

Shared by NobleBlocks on Sep 1, 2019 • 12:00 AM UTC

Authors:

Köhne CH

Karthaus M

Mineur L

Abstract

Objective Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location and early tumour shrinkage on outcomes.Methods Patients with...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!